Consolidated Statement Of Income

Modalis Therapeutics Corporation - Filing #7312187

Concept	2024-01-01 to 2024-06-30	2023-01-01 to 2023-06-30
Consolidated statement of income
Statement of income
Operating expenses
Selling, general and administrative expenses	122,437,000 JPY	138,360,000 JPY
Operating expenses
Operating expenses
Operating expenses - general
Remuneration for directors (and other officers)	25,590,000 JPY	23,130,000 JPY
General and administrative expenses
Salaries	—	—
Operating expenses
Research and development expenses	716,518,000 JPY	906,431,000 JPY
Operating profit (loss)	-838,956,000 JPY	-1,044,792,000 JPY
Ordinary profit (loss)	-780,152,000 JPY	-995,474,000 JPY
Non-operating income	63,052,000 JPY	54,660,000 JPY
Interest income	8,000 JPY	14,000 JPY
Selling, general and administrative expenses
Non-operating income
Other	11,000 JPY	8,000 JPY
Non-operating expenses
Interest expenses	2,057,000 JPY	2,212,000 JPY
Non-operating expenses	4,248,000 JPY	5,343,000 JPY
Share issuance costs	2,190,000 JPY	2,837,000 JPY
Extraordinary losses	188,000 JPY	37,146,000 JPY
Impairment losses	188,000 JPY	37,146,000 JPY
Profit (loss) before income taxes	-780,340,000 JPY	-1,032,620,000 JPY
Income taxes - current	606,000 JPY	607,000 JPY
Extraordinary losses
Income taxes	606,000 JPY	607,000 JPY
Profit (loss)	-780,946,000 JPY	-1,033,228,000 JPY
Profit (loss) attributable to owners of parent	-780,946,000 JPY	-1,033,228,000 JPY
Other comprehensive income
Foreign currency translation adjustment	8,801,000 JPY	-1,676,000 JPY
Other comprehensive income	8,801,000 JPY	-1,676,000 JPY
Profit attributable to
Comprehensive income	-772,145,000 JPY	-1,034,904,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent	-772,145,000 JPY	-1,034,904,000 JPY